Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus

Apr 19 2022

• By Alaric DeArment

Moderna announced Phase II/III data for its bivalent mRNA-1273.211 vaccine candidate • Source: Alamy

Related Content

Moderna’s COVID Vaccine Had Longer FDA Review Than Pfizer’s; Similar Post-Market Requirements

Feb 01 2022

Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route

Jan 26 2022

Related Companies

Moderna, Inc.

Pfizer Inc.

BioNTech SE

Additional Topics

Vaccines Coronavirus COVID-19 Research & Development Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.